贝达药业：关于盐酸恩沙替尼胶囊上市许可申请获得欧洲药品管理局受理的公告

Core Viewpoint - Xcovery Holdings, a subsidiary of BeiGene, has received acceptance from the European Medicines Agency (EMA) for its marketing authorization application for ensartinib capsules, intended for the treatment of adult patients with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) [2] Group 1 - The marketing authorization application for ensartinib has been officially accepted by the EMA [2] - The drug is specifically aimed at treating adult patients with ALK-positive locally advanced or metastatic NSCLC [2]